The company reiterated its FY25 GAAP net loss guidance of between $1.03B-$1.09B, which includes estimated non-cash stock-based compensation expense of between $115M-$130M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines reports Q3 EPS ($1.61), consensus ($1.41)
- Boeing upgraded, Charter downgraded: Wall Street’s top analyst calls
- Revolution Medicines initiated with an Outperform at RBC Capital
- Revolution Medicines: Promising Oncology Leader with Strategic Advancements and Competitive Edge
- Revolution Medicines Advances RAS(ON) Inhibitor Study in Gastrointestinal Cancers